A new study by Mayo Clinic, Boston University School of Public Health, and the pharmaceutical company Sanofi’s department of Global Evidence & Value Development has found the prevalence of MPN patients living in the United States to be much higher than previously assumed. They recently concluded a study which used two major insurance claims databases to identify nearly 300,000 people with essential thrombocythemia, myelofibrosis, and polycythemia vera in the United States. Their findings were reported at the American Society of Hematology annual meeting in 2012 and in a recent scientific publication.
The breakdown between patient groups is:
MF – 12, 812
PV – 148, 363
ET – 134, 534
This is the first study utilizing two large national US claims databases to estimate prevalence of MPN disorders (IMPACT and MARKETSCAN).